Champions Oncology, Inc. Announces Resignation of Abba David Poliakoff as Board of Director
February 12, 2021 at 09:27 pm IST
Share
Abba David Poliakoff informed the Board of Directors of Champions Oncology, Inc. of his intention to resign as a director of the company effective immediately. His resignation was for personal reasons and was not due to any disagreement with the company. To fill the vacancy created by Mr. Poliakoff's resignation, on February 8, 2021, the Board appointed Robert Brainin to serve as a member of the Board, effective immediately. Mr. Brainin has over 15 years of experience in the global life sciences and healthcare fields. He was most recently the Chief Executive Officer of Genuity Science from March 2018 to January 2021, also serving as a director from June 2020 until January 2021.
Champions Oncology, Inc. is a technology-enabled research organization engaged in creating transformative technology solutions to be utilized in drug discovery and development. The Company's research center operates in both regulatory and non-regulatory environments and consists of a comprehensive set of computational and experimental research platforms. The Companyâs TumorGraft Technology Platform (The Platform) provides select services to pharmaceutical and biotechnology companies. Its software as-a-service business is centered around its software platform and data tool, Lumin Bioinformatics (Lumin), which contains comprehensive information derived from its research services and clinical studies. Its drug discovery and development business leverage the computational and experimental capabilities within its platforms. Its discovery strategy utilizes its datacenter, coupled with artificial intelligence and other advanced computational analytics, to identify therapeutic targets.
CHAMPIONS ONCOLOGY, INC. 
